S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
The How and Why of Investing in Gold Stocks
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
Trump says he took the Fifth in NY civil investigation
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
Investors Look to Capitalize on the Budding Green Revolution (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
The How and Why of Investing in Gold Stocks
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
Trump says he took the Fifth in NY civil investigation
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
Investors Look to Capitalize on the Budding Green Revolution (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
The How and Why of Investing in Gold Stocks
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
Trump says he took the Fifth in NY civil investigation
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
Investors Look to Capitalize on the Budding Green Revolution (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
The How and Why of Investing in Gold Stocks
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
Trump says he took the Fifth in NY civil investigation
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
Investors Look to Capitalize on the Budding Green Revolution (Ad)
NASDAQ:GLYC

GlycoMimetics - GLYC Stock Forecast, Price & News

$0.89
+0.09 (+11.24%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.81
$0.90
50-Day Range
$0.54
$0.90
52-Week Range
$0.51
$2.50
Volume
219,616 shs
Average Volume
126,473 shs
Market Capitalization
$46.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

GlycoMimetics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
854.5% Upside
$8.50 Price Target
Short Interest
Healthy
1.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.67mentions of GlycoMimetics in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.24) to ($0.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.66 out of 5 stars

Medical Sector

220th out of 1,108 stocks

Pharmaceutical Preparations Industry

96th out of 542 stocks

GLYC stock logo

About GlycoMimetics (NASDAQ:GLYC) Stock

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

GlycoMimetics Trading Up 11.2 %

Shares of NASDAQ:GLYC opened at $0.89 on Thursday. The stock has a fifty day simple moving average of $0.66 and a two-hundred day simple moving average of $0.87. The stock has a market capitalization of $46.68 million, a price-to-earnings ratio of -0.74 and a beta of 1.85. GlycoMimetics has a 12-month low of $0.51 and a 12-month high of $2.50.

Analyst Upgrades and Downgrades

GLYC has been the subject of a number of research analyst reports. StockNews.com initiated coverage on GlycoMimetics in a research note on Friday, August 5th. They issued a "hold" rating for the company. HC Wainwright lowered their target price on GlycoMimetics from $14.00 to $13.00 and set a "buy" rating for the company in a research note on Thursday, August 4th.

Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

GLYC Stock News Headlines

What Makes GlycoMimetics (GLYC) a New Buy Stock
GlycoMimetics (NASDAQ:GLYC) Now Covered by StockNews.com
GlycoMimetics (GLYC) Q2 2022 Earnings Call Transcript
Recap: GlycoMimetics Q2 Earnings - Benzinga
GlycoMimetics: Q2 Earnings Snapshot - Greenwich Time
See More Headlines
Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

GLYC Company Calendar

Last Earnings
11/02/2021
Today
8/11/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLYC
Employees
52
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.50
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+349.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-63,430,000.00
Pretax Margin
-34,819.44%

Debt

Sales & Book Value

Annual Sales
$1.16 million
Book Value
$1.06 per share

Miscellaneous

Free Float
48,230,000
Market Cap
$46.68 million
Optionable
Optionable
Beta
1.85

Key Executives

  • Mr. Harout Semerjian (Age 52)
    CEO, Pres & Director
    Comp: $481.96k
  • Mr. Brian M. Hahn (Age 48)
    Sr. VP & CFO
    Comp: $804.38k
  • Dr. John L. Magnani (Age 69)
    Sr. VP of Research & Chief Scientific Officer
    Comp: $803.16k
  • Ms. Stephanie R. Irish (Age 51)
    VP of Accounting
  • Mr. Christian Dinneen-Long
    VP, Corp. Counsel & Corp. Sec.
  • Mr. Armand Girard (Age 53)
    Chief Bus. Officer and Sr. VP of Strategy & Corp. Devel.
  • Mr. Bruce Johnson
    Sr. VP & Chief Commercial Officer













GLYC Stock - Frequently Asked Questions

Should I buy or sell GlycoMimetics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GLYC shares.
View GLYC analyst ratings
or view top-rated stocks.

What is GlycoMimetics' stock price forecast for 2022?

2 brokers have issued 12 month target prices for GlycoMimetics' shares. Their GLYC share price forecasts range from $4.00 to $13.00. On average, they anticipate the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 854.5% from the stock's current price.
View analysts price targets for GLYC
or view top-rated stocks among Wall Street analysts.

How have GLYC shares performed in 2022?

GlycoMimetics' stock was trading at $1.44 at the beginning of the year. Since then, GLYC shares have decreased by 38.2% and is now trading at $0.8905.
View the best growth stocks for 2022 here
.

When is GlycoMimetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our GLYC earnings forecast
.

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) posted its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.32) by $0.02. The biotechnology company had revenue of $0.09 million for the quarter. During the same period in the previous year, the company earned ($0.29) EPS.

What other stocks do shareholders of GlycoMimetics own?

What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

How do I buy shares of GlycoMimetics?

Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GlycoMimetics' stock price today?

One share of GLYC stock can currently be purchased for approximately $0.89.

How much money does GlycoMimetics make?

GlycoMimetics (NASDAQ:GLYC) has a market capitalization of $46.68 million and generates $1.16 million in revenue each year. The biotechnology company earns $-63,430,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.

How can I contact GlycoMimetics?

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The official website for the company is www.glycomimetics.com. The biotechnology company can be reached via phone at (240) 243-1201, via email at sannes@annesassociates.com, or via fax at 301-738-2137.

This page (NASDAQ:GLYC) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.